<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652349</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ROZE-302</org_study_id>
    <nct_id>NCT04652349</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia</brief_title>
  <official_title>A Randomized, Double-Blinded, Multi-center, Phase 3 Study to Evaluate Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and clinical efficacy of HGP1910 and&#xD;
      HCP1903 in patients with primary hypercholesterolemia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Actual">January 14, 2021</completion_date>
  <primary_completion_date type="Actual">December 17, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change(%) from baseline in LDL-C at week 8</measure>
    <time_frame>baseline, 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change(%) from baseline in LDL-C at week 4</measure>
    <time_frame>baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change(%) from baseline in LDL-C, TC, HDL-C, non-HDL-C</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change(%) from baseline in Apo A1, Apo B, lipoprotein (a)</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving LDL-C treatment goals by cardiovascular Risk Category</measure>
    <time_frame>baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>HGP1910</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HCP1903</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HGP1909</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HGP1911</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP1910</intervention_name>
    <description>Take it once daily for 8 weeks orally.</description>
    <arm_group_label>HGP1910</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1903</intervention_name>
    <description>Take it once daily for 8 weeks orally.</description>
    <arm_group_label>HCP1903</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP1909</intervention_name>
    <description>Take it once daily for 8 weeks orally.</description>
    <arm_group_label>HGP1909</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP1911</intervention_name>
    <description>Take it once daily for 8 weeks orally.</description>
    <arm_group_label>HGP1911</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants aged ≥ 19 years&#xD;
&#xD;
          -  Participants who have voluntarily given written consent to participate in this&#xD;
             clinical trial&#xD;
&#xD;
          -  Participants with LDL-C ≤ 250mg/dL and TG &lt; 500mg/dL at Visit 1&#xD;
&#xD;
          -  Participants with LDL-C ≤ 250mg/dL, TG &lt; 500 mg/dL and satisfied criteria according to&#xD;
             cardiovascular risk category at Visit 2 (after at least 4 weeks of TLC)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active liver disease and severe liver impairment&#xD;
&#xD;
          -  Patients with severe renal failure (eGFR &lt; 30 mL/min/1.73 m2 at Visit 1)&#xD;
&#xD;
          -  Patients with type I diabetes or uncontrolled type 2 diabetes&#xD;
&#xD;
          -  Patients with acute hypertension or uncontrolled hypertension (sitSBP ≥ 180 mmHg or&#xD;
             sitDBP ≥ 110 mmHg at Visit 1)&#xD;
&#xD;
          -  Patients with symptomatic orthostatic hypotension&#xD;
&#xD;
          -  Patients with NYHA class III~IV heart failure, CCSA class III~IV angina, ventricular&#xD;
             arrhythmia, severe hemorrhagic or ischemic cerebrovascular diseases, transient&#xD;
             ischemic attacks (TIAs), acute coronary syndrome or a history of angioplasty,&#xD;
             percutaneous coronary intervention, or coronary artery bypass surgery within six&#xD;
             months before Visit 1.&#xD;
&#xD;
          -  Patients who were diagnosed with a malignant tumor within five years before Visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

